Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Transplantation inc owns the patent... i was wrong . Some of the Postings made in 2015/16 dissappeard on the web page . To be honest i dont know who owns what but i wish all good luck around.
I remember different Postings There some years ago . Where i can find that ownership ? However its trading strange . Good luck if youre invested .
Trading unchanged . Someone seems to sell what is possible after News out
Was a long time not here but i remember this Company has no website or valid Email so i ask myself where are the people writing to . Therapycells.com we have learned 2 years ago has nothing to do with tcel . I remember even the patent and all rights are only owned by a new Company named contravaccine .
For Sure . That could Happen . Its a Kind of lottery Ticket . At the Moment the story is dead .
The Problem is That he founded a seperate Company to do this ( contravaccine/ Transplantation inc Or whatever) . Tcel is not Connected to this . They Posted That on Therapycells.com years ago as the hype Had its peak . I Remember Even That Homepage is Not owned by tcel inc . Its a Wortless Shell . Im sorry
Transplantation Ltd is the owner of the patent ( not tcel ) and the other company works with the patent . Tcel is granted a right but there seems nobody left in the house .
Transplantation Ltd and Contravaccine Ltd are the names . Check website
Check the news from last year . Mr Cassy works with the patent but he founded another company to do it . Since that day it was clear that tcel is worthless .
@ 1,25 is an gap Open . Thats the Ultimate Maximum . From That Point it will drop like a Stone
Tkstf ... 3D Printer ... making Profit , Low m Cap , Low Float .... Volume up and Techn. breakout
Tkstf ... 3 d Printer ... Same sector as Sigma labs .... Volume up , Chart breakout !! Making Profit and Low m Cap
The fundamental facts Looking very good . Its quite unusual that a Company in this promising sector making Profit ! and is traded with a market Cap of 3 or 4 m Dollar . Take a Look @ Sigma labs . The Last days this Stock , comparable with tkstf , is flying . I exspect a Major run to come next days .
Tkstf ... Same Story as Sigma labs ... Chart breakout , Volume up
Tkstf .... Same Story as Sigma labs ... Chart breakout !!!
Tkstf ... 3 d Printer ... Chart Breakout
Youre still invested ?? Just buying here .... Chart Looks like Huge Move to come now
Charts , figures and low market Cap Looks like this Thing will fly next Weeks .
Watching Sigma labs und tinkerine Studios . Sigma labs Just exploding will this one Follow ??
As i wrote
For what ? ??
Waiting for 0,0006 to get in
Looks like Company selling Shares today as usuel
Share Structure
Market Value1 $1,040,282 a/o Sep 22, 2015
Authorized Shares 2,900,000,000 a/o Mar 31, 2015
Outstanding Shares 1,733,804,145 a/o Mar 31, 2015
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 329,542,935 a/o Jun 06, 2014
Par Value Not Available
Transfer Agent(s)
Action Stock Transfer Corporation
"With a growing level of trial success in horses, Therapy Cells' target is to gain FDA approval, and in short order has direct application for human tendon repair," Dr Casey says. "An initial valuation of $30 million USD for our science and technology has been appraised. FDA approval for clinical use of this technology in the Human, will likely increase this factor by at least 10 times."
Remember This ! Now its Starting ' "With a growing level of trial success in horses, Therapy Cells' target is to gain FDA approval, and in short order has direct application for human tendon repair," Dr Casey says. "An initial valuation of $30 million USD for our science and technology has been appraised. FDA approval for clinical use of this technology in the Human, will likely increase this factor by at least 10 times."
Ma cap Around 1 m USD ... Funding of 5.7 m .... Potential of 2000 m ?
Last Time This Shot up to some Pennies
" If all contract options are exercised, the total award of up to $5.7 million will support the preclinical, manufacturing and clinical development activities necessary to continu
News Out ! Receives Funding From Sofinnova Partners To Advance Development Of Tissue And Organ Repair: Awarded $5.7 Million In Funding [Market News Publishing (US)]
THERAPY CELLS INC
THERAPY CELLS INC ("TCEL-0") - Receives Funding From Sofinnova Partners To Advance - Development Of Tissue And Organ Repair: Awarded $5.7 Million - In Funding
Therapy Cells, Inc. (Therapy Cell or the Company), an early-stage bioengineering company developing products that address unmet medical needs in the areas of cell re-growth in damaged tissue and organs, announced today Sofinnova Partners exercised its option to advance the development of Therapy Cells patented cell process. The overall objectives of the contract are to advance the development of Therapy Cells technology, obtain FDA approval, start clinical trials and bring equine products to market. The exercised option will provide Therapy Cells with an initial $2.7 million in funding. If all contract options are exercised, the total award of up to $5.7 million will support the preclinical, manufacturing and clinical development activities necessary to continue to advance our patented process with the US Food and Drug Administration (FDA).
Therapy Cells CFO, Mr. John Meredith said, "This investment by Sofinnova Partners enables us to begin efforts to open clinical trial sites during next quarter for our Phase I study, following the protocols which we expect the FDA to approve in the very near future." Mr. Meredith, further commented that, "We are excited about the development and commercialization of our patented Therapy Cell technology for the treatment of cell re-growth and repair. The body of evidence supporting the use of Therapy Cells in tissue and organ re-growth is well established, and we believe our product provides a number of advantages over any other stem cell products, including improved bioavailability and more consistent results."
TCEL will use this funding to immediately accelerate its development program, which is focused on the treatment of damaged tissue, cells, tendons and organs using our patented process. In particular, Therapy Cells will shortly be commencing a Phase I clinical trial designed to determine the safety and effectiveness on patients with major heart, lung, liver or pancreas damage. Preliminary results are expected to be available by mid 2016.
Therapy Cells would also like to announce that their new website is nearing completion and will launch in the following weeks. In addition they plan to bring the equine Therapy Cells product to market within the next 30 days for immediate sale and disbursement. We predict this will bring about an immediate positive impact on our bottom line and will bring added value to our long term investors.
I Guess Most did Not See News . Quite calm Here . Modt waited Nearly 2 years for This news
Tcel Funding News ! Receives Funding From Sofinnova Partners To Advance Development Of Tissue And Organ Repair: Awarded $5.7 Million In Funding [Market News Publishing (US)]
THERAPY CELLS INC
THERAPY CELLS INC ("TCEL-0") - Receives Funding From Sofinnova Partners To Advance - Development Of Tissue And Organ Repair: Awarded $5.7 Million - In Funding
Therapy Cells, Inc. (Therapy Cell or the Company), an early-stage bioengineering company developing products that address unmet medical needs in the areas of cell re-growth in damaged tissue and organs, announced today Sofinnova Partners exercised its option to advance the development of Therapy Cells patented cell process. The overall objectives of the contract are to advance the development of Therapy Cells technology, obtain FDA approval, start clinical trials and bring equine products to market. The exercised option will provide Therapy Cells with an initial $2.7 million in funding. If all contract options are exercised, the total award of up to $5.7 million will support the preclinical, manufacturing and clinical development activities necessary to continue to advance our patented process with the US Food and Drug Administration (FDA).
Therapy Cells CFO, Mr. John Meredith said, "This investment by Sofinnova Partners enables us to begin efforts to open clinical trial sites during next quarter for our Phase I study, following the protocols which we expect the FDA to approve in the very near future." Mr. Meredith, further commented that, "We are excited about the development and commercialization of our patented Therapy Cell technology for the treatment of cell re-growth and repair. The body of evidence supporting the use of Therapy Cells in tissue and organ re-growth is well established, and we believe our product provides a number of advantages over any other stem cell products, including improved bioavailability and more consistent results."
TCEL will use this funding to immediately accelerate its development program, which is focused on the treatment of damaged tissue, cells, tendons and organs using our patented process. In particular, Therapy Cells will shortly be commencing a Phase I clinical trial designed to determine the safety and effectiveness on patients with major heart, lung, liver or pancreas damage. Preliminary results are expected to be available by mid 2016.
Therapy Cells would also like to announce that their new website is nearing completion and will launch in the following weeks. In addition they plan to bring the equine Therapy Cells product to market within the next 30 days for immediate sale and disbursement. We predict this will bring about an immediate positive impact on our bottom line and will bring added value to our long term investors.
http://www.otcmarkets.com/stock/TCEL/news Receives Funding From Sofinnova Partners To Advance Development Of Tissue And Organ Repair: Awarded $5.7 Million In Funding [Market News Publishing (US)]
THERAPY CELLS INC
THERAPY CELLS INC ("TCEL-0") - Receives Funding From Sofinnova Partners To Advance - Development Of Tissue And Organ Repair: Awarded $5.7 Million - In Funding
Therapy Cells, Inc. (Therapy Cell or the Company), an early-stage bioengineering company developing products that address unmet medical needs in the areas of cell re-growth in damaged tissue and organs, announced today Sofinnova Partners exercised its option to advance the development of Therapy Cells patented cell process. The overall objectives of the contract are to advance the development of Therapy Cells technology, obtain FDA approval, start clinical trials and bring equine products to market. The exercised option will provide Therapy Cells with an initial $2.7 million in funding. If all contract options are exercised, the total award of up to $5.7 million will support the preclinical, manufacturing and clinical development activities necessary to continue to advance our patented process with the US Food and Drug Administration (FDA).
Therapy Cells CFO, Mr. John Meredith said, "This investment by Sofinnova Partners enables us to begin efforts to open clinical trial sites during next quarter for our Phase I study, following the protocols which we expect the FDA to approve in the very near future." Mr. Meredith, further commented that, "We are excited about the development and commercialization of our patented Therapy Cell technology for the treatment of cell re-growth and repair. The body of evidence supporting the use of Therapy Cells in tissue and organ re-growth is well established, and we believe our product provides a number of advantages over any other stem cell products, including improved bioavailability and more consistent results."
TCEL will use this funding to immediately accelerate its development program, which is focused on the treatment of damaged tissue, cells, tendons and organs using our patented process. In particular, Therapy Cells will shortly be commencing a Phase I clinical trial designed to determine the safety and effectiveness on patients with major heart, lung, liver or pancreas damage. Preliminary results are expected to be available by mid 2016.
Therapy Cells would also like to announce that their new website is nearing completion and will launch in the following weeks. In addition they plan to bring the equine Therapy Cells product to market within the next 30 days for immediate sale and disbursement. We predict this will bring about an immediate positive impact on our bottom line and will bring added value to our long term investors.
News Out
News Out Mega News ! TCEL US: Receives Funding From Sofinnova Partners To Advance Dev
THERAPY CELLS INC ("TCEL-0")
- Receives Funding From Sofinnova Partners To Advance
- Development Of Tissue And Organ Repair: Awarded $5.7 Million
- In Funding
Therapy Cells, Inc. (Therapy Cell or the Company), an early-stage bioengineering company developing products that address unmet medical needs in the areas of cell re-growth in damaged tissue and organs, announced today Sofinnova Partners exercised its option to advance the development of Therapy Cells patented cell process. The overall objectives of the contract are to advance the development of Therapy Cells technology, obtain FDA approval, start clinical trials and bring equine products to market. The exercised option will provide Therapy Cells with an initial $2.7 million in funding. If all contract options are exercised, the total award of up to $5.7 million will support the preclinical, manufacturing and clinical development activities necessary to continue to advance our patented process with the US Food and Drug Administration (FDA).
Therapy Cells CFO, Mr. John Meredith said, "This investment by Sofinnova Partners enables us to begin efforts to open clinical trial sites during next quarter for our Phase I study, following the protocols which we expect the FDA to approve in the very near future." Mr. Meredith, further commented that, "We are excited about the development and commercialization of our patented Therapy Cell technology for the treatment of cell re-growth and repair. The body of evidence supporting the use of Therapy Cells in tissue and organ re-growth is well established, and we believe our product provides a number of advantages over any other stem cell products, including improved bioavailability and more consistent results."
TCEL will use this funding to immediately accelerate its development program, which is focused on the treatment of damaged tissue, cells, tendons and organs using our patented process. In particular, Therapy Cells will shortly be commencing a Phase I clinical trial designed to determine the safety and effectiveness on patients with major heart, lung, liver or pancreas damage. Preliminary results are expected to be available by mid 2016.
Therapy Cells would also like to announce that their new website is nearing completion and will launch in the following weeks. In addition they plan to bring the equine Therapy Cells product to market within the next 30 days for immediate sale and disbursement. We predict this will bring about an immediate positive impact on our bottom line and will bring added value to our long term investors.
News Out
Mega News ! TCEL US: Receives Funding From Sofinnova Partners To Advance Dev
THERAPY CELLS INC ("TCEL-0")
- Receives Funding From Sofinnova Partners To Advance
- Development Of Tissue And Organ Repair: Awarded $5.7 Million
- In Funding
Therapy Cells, Inc. (Therapy Cell or the Company), an early-stage bioengineering company developing products that address unmet medical needs in the areas of cell re-growth in damaged tissue and organs, announced today Sofinnova Partners exercised its option to advance the development of Therapy Cells patented cell process. The overall objectives of the contract are to advance the development of Therapy Cells technology, obtain FDA approval, start clinical trials and bring equine products to market. The exercised option will provide Therapy Cells with an initial $2.7 million in funding. If all contract options are exercised, the total award of up to $5.7 million will support the preclinical, manufacturing and clinical development activities necessary to continue to advance our patented process with the US Food and Drug Administration (FDA).
Therapy Cells CFO, Mr. John Meredith said, "This investment by Sofinnova Partners enables us to begin efforts to open clinical trial sites during next quarter for our Phase I study, following the protocols which we expect the FDA to approve in the very near future." Mr. Meredith, further commented that, "We are excited about the development and commercialization of our patented Therapy Cell technology for the treatment of cell re-growth and repair. The body of evidence supporting the use of Therapy Cells in tissue and organ re-growth is well established, and we believe our product provides a number of advantages over any other stem cell products, including improved bioavailability and more consistent results."
TCEL will use this funding to immediately accelerate its development program, which is focused on the treatment of damaged tissue, cells, tendons and organs using our patented process. In particular, Therapy Cells will shortly be commencing a Phase I clinical trial designed to determine the safety and effectiveness on patients with major heart, lung, liver or pancreas damage. Preliminary results are expected to be available by mid 2016.
Therapy Cells would also like to announce that their new website is nearing completion and will launch in the following weeks. In addition they plan to bring the equine Therapy Cells product to market within the next 30 days for immediate sale and disbursement. We predict this will bring about an immediate positive impact on our bottom line and will bring added value to our long term investors.
Funding News ! They got the Money !
Volume up
News Out !